PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15114695

[Structure-activity relationship analysis].

Yoichi Hayakawa
View original source ↗Export metadata ↓

Abstract

All samples for anticancer drug screening were classified according to their structural features and their structure-activity relationships were analyzed. Synthetic gymnastatin analogs including JCI: 11788 and JCI: 11786 altered their selectivity for protein kinase inhibition with the length of a fatty acid chain. Although a new inhibitor of tubulin depolymerization, JCI: 11578, displayed a high correlation to known tubulin binders, novel inhibitors of tubulin polymerization, JCI: 11534, JCI: 11675 and JCI: 11676, exhibited poor correlations to tubulin binders. JCI: 11403 and JCI: 11407 inhibited topoisomerase I selectively and appear to belong to a new family of topoisomerase inhibitors. They are expected to be important key compounds for structure-activity relationship analysis as well as new lead compounds for anticancer drugs.

Explore related subjects

Antineoplastic AgentsBenzamidesCamptothecinDocetaxelDrug Screening Assays, AntitumorEpothilonesGefitinibImatinib MesylateIrinotecanMacrolidesOligopeptidesPaclitaxelPiperazinesPyrimidinesQuinazolinesStructure-Activity RelationshipTaxoidsTopotecanVinblastineJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yoichi Hayakawa. 2004. [Structure-activity relationship analysis].. https://pubmed.ncbi.nlm.nih.gov/15114695/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗
PubMed2005

Targeted therapy: for kids, too.

Innovative hypothesis-driven clinical trials have achieved major successes over the past several decades in treating children and adolescents with cancer. DNA-damaging cytotoxic agents have cured children with cancer. While the mission is not yet accomplished, chemotherapy has been validated. None of these drugs were designed specifically for a pediatric disease. Continued progress will require new strategies. Now being tested for adult cancers, these strategies include gene therapy, immunotherapy, cancer prevention, and signal transduction inhibitor (STI) therapy. Of these, the most promising is STI therapy, also known as molecular therapeutics or targeted therapy. For this therapy to succeed, components of signal transduction (i.e., candidate drug targets) must be identified, the targets relevant to cancers, and the drugs available for trial. Because STI therapy is biologically driven and because therapy will be tailored depending on the molecular profile of a specific patient's tumor, clinical pediatric oncologists will need to acquire greater understanding of signaling pathways and their therapeutic relevance. With examples drawn from pediatric oncology, the critical steps in the pre-clinical development of targeted therapy are reviewed here.

Antineoplastic Agents↗
PubMed2005

Retinoid-related molecule AGN193198 potently induces G2M arrest and apoptosis in bladder cancer cells.

The novel synthetic retinoid-related molecule 4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-oxo-propenyl]benzoic acid (AGN193198) neither binds effectively to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) nor transactivates in RAR- and RXR-mediated reporter assays. Even so, AGN193198 is potent in inducing apoptosis in human prostate and breast carcinoma cells (Keedwell et al., Cancer Res 2004;64:3302-12). Here, we extend these findings to show that AGN193198 potently and rapidly induces apoptosis in bladder carcinoma cell lines. One micromolar of AGN193198 completely abolished the growth of the transitional cell carcinoma lines UM-UC-3 and J82, and the squamous cell carcinoma line SCaBER; the transitional cell papilloma line RT-4 was slightly less sensitive to the growth inhibitory effect of AGN193198. Treated cells accumulated in the G2M phase of the cell cycle. This was accompanied by apoptosis, as revealed by staining cells for exposure of phosphatidylserine at their surface (binding of Annexin V) and FACS analysis of propidium iodide labeled cells. As reported for prostate cancer cells, AGN193198 provoked rapid activation of caspases-3 (by 6 hr), -8 (by 16 hr) and -9 (by 6 hr) in bladder cancer cells. These findings suggest that AGN193198 and related compounds, whose mechanism of action does not appear to involve RARs and RXRs, may be useful in the treatment of bladder cancer.

Antineoplastic Agents↗